Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
boston top stories
editas medicine
gene editing
life sciences
national blog main
boston
crispr
san francisco blog main
allergan
clinical trials
crispr-cas9
cynthia collins
katrine bosley
national top stories
san francisco top stories
abbvie
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
alzheimer's disease
andrew oxtoby
babies
base editing
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
broad institute
cas13
ceo
clinical hold
clinical study
combination
commissioner
congress
What
editas
4
×
crispr
editing
gene
medicine
cas
ceo
experimental
katrine
abbvie
allergan
alliance
beam
big
bio
biotech
blessing
bosley
bosley's
bosley’s
bridge
bucks
check
clinical
crime
cusp
depart
departure
editor
exit
exits
founders
genetic
gotten
guiding
harvard
humans
jump
mass
medicines
Language
unset
Current search:
biotech
×
editas
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M